Fri November 4th, 2016
Growth of Nuclear Medicine/Radiopharmaceuticals - Increasing Incidence and Prevalence of Cancer and Cardiac Ailments.
Download FREE PDF Brochure@ http://tinyurl.com/hms4ylu Growth of the overall nuclear medicine market can be attributed to factors such as the increasing number of chronic diseases like cancer, development of alpha radiotherapy, and investments through public-private partnerships. The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 Billion by 2021 from USD 4.67 Billion in 2016, growing at a CAGR of 9.3% during the forecast period. The global market is segmented on the basis of type, application, procedural volume, and region. On the basis of type, the diagnostic radiopharmaceuticals segment is expected to command the largest share of the global market; it is also expected to grow at the highest CAGR during the forecast period. The large market share and high growth rate of this segment can be attributed to the production of MO-99 in the U.S., approval of radiopharmaceuticals by the FDA, new irradiation facility in Germany, installation of PET scanners in India. Scope:- Nuclear Medicine Market, by Procedural Volumes Diagnostic Procedures SPECT Radiopharmaceuticals PET Radiopharmaceuticals Therapeutic Procedures Beta Emitters Alpha Emitters Brachytherapy Major players in the global nuclear medicine market include Cardinal Health Inc. (U.S.), Mallinckrodt plc (Ireland), GE Healthcare (U.K.), Lantheus Medical Imaging, Inc. (U.S.), Bayer AG (Germany), Bracco Imaging S.p.A (Italy).